Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2004-03-19
2010-06-08
Ton, Thaian N (Department: 1632)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C435S404000
Reexamination Certificate
active
07732199
ABSTRACT:
This invention provides populations human cells of the cardiomyocyte lineage. The cells are obtained by causing cultures of pluripotent stem cells to differentiate in vitro, and then harvesting cells with certain phenotypic features. Differentiated cells bear cell surface and morphologic markers characteristic of cardiomyocytes, and a proportion of them undergo spontaneous periodic contraction. Highly enriched populations of cardiomyocytes and their replicating precursors can be obtained, suitable for use in a variety of applications, such as drug screening and therapy for cardiac disease.
REFERENCES:
patent: 5543318 (1996-08-01), Smith et al.
patent: 5733727 (1998-03-01), Field
patent: 5843780 (1998-12-01), Thomson
patent: 5928943 (1999-07-01), Franz et al.
patent: 6015671 (2000-01-01), Field
patent: 6099832 (2000-08-01), Mickle et al.
patent: 6110459 (2000-08-01), Mickle et al.
patent: 6245566 (2001-06-01), Gearhart et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6387369 (2002-05-01), Pittenger et al.
patent: 6399300 (2002-06-01), Field
patent: 6534052 (2003-03-01), Xiao et al.
patent: 7368420 (2008-05-01), Walsh
patent: 7425448 (2008-09-01), Xu
patent: 7452718 (2008-11-01), Gold et al.
patent: 2002/0061837 (2002-05-01), Lough, Jr. et al.
patent: 2002/0142457 (2002-10-01), Umezawa et al.
patent: 2002/0146678 (2002-10-01), Benvenisty
patent: 2004/0005701 (2004-01-01), Xu et al.
patent: 2004/0022367 (2004-02-01), Talalai
patent: 2005/0037489 (2005-02-01), Gepstein et al.
patent: 2005/0054092 (2005-03-01), Xu et al.
patent: 2005/0164382 (2005-07-01), Xu
patent: 2005/0214938 (2005-09-01), Xu et al.
patent: 2005/0227353 (2005-10-01), Mummery
patent: 2005/0266554 (2005-12-01), D'Amour et al.
patent: 2009/0017465 (2009-01-01), Xu
patent: 2009/0047739 (2009-02-01), Xu et al.
patent: 729377 (2001-02-01), None
patent: WO 92/13066 (1992-08-01), None
patent: WO 95/14079 (1995-05-01), None
patent: WO 99/49015 (1999-09-01), None
patent: WO 00/06701 (2000-02-01), None
patent: WO 00/70021 (2000-11-01), None
patent: WO 00/78119 (2000-12-01), None
patent: WO 01/22978 (2001-04-01), None
patent: WO 01/48151 (2001-07-01), None
patent: WO 01/048151 (2001-07-01), None
patent: WO 01/51616 (2001-07-01), None
patent: WO 01/53465 (2001-07-01), None
patent: WO 01/68814 (2001-09-01), None
patent: WO 02/09650 (2002-02-01), None
patent: WO 02/13760 (2002-02-01), None
patent: WO 02/19893 (2002-03-01), None
patent: WO 02/30206 (2002-04-01), None
patent: WO 02/083864 (2002-10-01), None
patent: WO 03/006950 (2003-01-01), None
patent: WO 2004/081205 (2004-09-01), None
Murrell, WG et al. Mech Ageing Dev 77(2):abstract, 1994.
Verfaillie, CM. et al. Hematotlogy 2002:369-391, 2002.
Takahshi, K et al. J Cardiovasc Pharm 41(5):726-0733, 2003.
Nair, P and RP Nair. Indian J Exp Biol 35(5):abstract, 1997.
Pandur, P. Biol Cell 97:197-210, 2005.
Schuldiner, M et al. PNAS 97(21):11307-11312, 2000.
Lim, J. & Bodnar, A., “Proteome analysis of conditioned medium from mouse embyronic fibroblast feeder layers which support the growth of human embryonic stem cells,”Proteomics2:1187-203 (2002).
Khamsi, R., “Market Watch,”Nature437:1231 (2005).
Murry, C. et al., “Muscle cell grafting for the treatment and prevention of heart failure,”J. Cardiac Failure8(6):S532-S541 (2002).
Rice, N. & Leinwand, L., “Skeletal myosin heavy chain function in cultured lung myofibroblasts,”J. Cell Biol. 163(1):119-29 (2003).
Shamblott, M. et al., “Human embryonic germ cell derivatives express a broad range of developmentally distinct markers and proliferate extensively in vitro,”Proc, Natl. Acad. Sci. USA98(1):113-8 (2001).
Thomson, J. et al., “Isolation of a primate embryonic stem cell line,”Proc. Natl. Acad. Sci. USA92:7844-8 (1995).
Caspi, O. & Gepstein, L., “Potential applications of human embryonic stem cell-derived cardiomyocytes,”Ann. N. Y. Acad. Sci. 1015:285-98 (2004).
Charron, F. & Nemer, M., “GATA transcription factors and cardiac development,”Semin. Cell Dev. Biol. 10(1):85-91 (1999).
Goh, G. et al., “Molecular and phenotypic analysis of human embryonic stem cell-derived cardiomyocytes,”Thromb. Haemost. 94:728-37 (2005).
Khamsi, R. “Geneticists Hail Variety Show, Map of DNA Differences will Help Experts Tailor Drugs,”Nature, online, 2 pages (Oct. 26, 2005).
Laflamme, M. et al., “Formation of human myocardium in the rat heart from human embryonic stem cells,”Am. J. Pathol. 167(3):663-71 (2005).
Strauer, B. et al., “Stem Cell Therapy in Perspective,”Circulation107:929-34 (2003).
Van Laake, L. et al., “Cardiomyocytes derived from stem cells,”Ann. Med. 37:499-512 (2005).
Xiao, Y-F. et al., “Cardiac application of embryonic stem cells,”Acta Physiologica Sinica55(5):493-504 (2003).
Xu, C. et al., “Cardiac Bodies: A novel culture method for enrichment of cardiomyocytes derived from human embryonic stem cells,”Stem Cells Dev. 15:631-9 (2006).
Czyz, J. et al., “Potential of embryonic and adult stem cells in vitro,”Biol. Chem. 384:1391-409 (2003).
Gerecht-Nir, S. et al., “Vascular gene expression and phenotypic correlation during differentiation of human embryonic stem cells,”Dev. Dyn. 232:487-97 (2005).
Oh, S. et al., “Human embryonic stem cells: technological challenges towards therapy,”Clin. Exp. Pharmacol. Physiol. 33:489-95 (2006).
“Alpha-1 adrenergic receptor,” Wikipedia entry, 4 pages, printed Mar. 26, 2009.
“Isoprenaline,” Wikipedia entry, 2 pages, printed Mar. 25, 2009.
Boheler, K. et al., “Differentiation of pluripotent embryonic stem cells into cardiomyocytes,”Circ. Res. 91:189-201 (2002).
Cerbai, E. et al. “Electrophysiologic effects of lercanidipine on repolarizing potassium currents,”J. Cardiovasc. Pharmacol. 36:584-91 (2000).
Corsini, A. et al. “Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes,”J. Cardiovasc. Pharmacol. 28:687-94 (1996).
De Pater, E. et al. “Distinct phases of cardiomyocyte differentiation regulate growth of the zebrafish heart,”Development136:1633-41(2009).
Feng, J. et al. “Antisense oligodeoxynucleotides direccted against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes,”Circ. Res. 80:572-9 (1997).
Goldman, B. et al., “Epidermal growth factor promotes a cardiomyoblastic phenotype in human fetal cardiac myocytes,”Exp. Cell Res. 228:237-45 (1996).
Piao, S. et al., “A simplified method for identification of human cardiac myosin heavy-chain isoforms,”Biotechnol. Appl. Biochem. 37:27-30 (2003).
Tweedie, D. et al. “The effect of alterations to action potential duration on Beta-adrenoceptor-mediated aftercontractions in human and guinea-pig ventricular myocytes,”J. Mol. Cell Cardiol. 29:1457-67 (1997).
Alsan et al., Regulation of avian cardiogenesis by Fgf8 signaling, Development, 129:1935 (2002).
Andree et al., BMP-2 induces expression of cardiac lineage markers and interferes with somite formation in chicken embryos, Mech. of Deve., 70:119 (1998).
Antin et al., Regulation of avian precardiac mesoderm development by insulin and insulin-like growth factors, J. Cell. Physiol. 168:42 (1996).
Arai et al., Murine cardiac progenitor cells require visceral embryonic endoderm and primitive streak for terminal differentiation, Dev. Dynamics 210:344 (1997).
Barron et al., Repuirement for BMP and FGF signaling during cardiogenic induction in non-precrdiac mesoderm is specific, transient, and cooperative, Dev. Dynamics 218:383 (2000).
Bauwens et al., Development of perfusion fed bioreactor for embryonic stem cell-derived cardiomyocyte generation: oxygen-mediated enhancement of cardiomyocyte output, biotechnology and bioengineering 90 (4):452 (2005).
Behfar et al., Stem cell differe
Gold Joseph D.
Xu Chunhui
Geron Corporation
Mittler E. Stewart
Noble Marcia S
Ton Thaian N
LandOfFree
Process for making transplantable cardiomyocytes from human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for making transplantable cardiomyocytes from human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for making transplantable cardiomyocytes from human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237569